Cardiac amyloidosis laboratory findings: Difference between revisions

Jump to navigation Jump to search
Line 11: Line 11:
* Serum [[troponin]]s: Cardiac troponins are elevated due to myonecrosis and small-vessel disease due to deposition of amyloid in the heart. Troponins are of both diagnostic and prognostic importance. Studies have shown worse survival rates in patients with systemic amyloidosis and cardiac involvement compared to those without cardiac involvement.
* Serum [[troponin]]s: Cardiac troponins are elevated due to myonecrosis and small-vessel disease due to deposition of amyloid in the heart. Troponins are of both diagnostic and prognostic importance. Studies have shown worse survival rates in patients with systemic amyloidosis and cardiac involvement compared to those without cardiac involvement.
* [[Atrial natriuretic peptide]]: Elevated in heart failure
* [[Atrial natriuretic peptide]]: Elevated in heart failure
* [[Brain natriuretic peptide]]: Elevated in heart failure
* [[Brain natriuretic peptide]]: Elevated in heart failure. N-terminal proBNP is the most sensitive marker of heart dysfunction in amyloid patients.
* Serum [[transthyretin]]  
* Serum [[transthyretin]]  
* Urinalysis for [[proteinuria]]
* Urinalysis for [[proteinuria]]

Revision as of 21:18, 4 May 2013

Cardiac amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiac Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac amyloidosis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac amyloidosis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac amyloidosis laboratory findings

CDC onCardiac amyloidosis laboratory findings

Cardiac amyloidosis laboratory findings in the news

Blogs on Cardiac amyloidosis laboratory findings

Directions to Hospitals Treating Cardiac amyloidosis

Risk calculators and risk factors for Cardiac amyloidosis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Aarti Narayan, M.B.B.S [3]; Lakshmi Gopalakrishnan, M.B.B.S. [4]

Overview

There is no specific diagnostic blood test, radiograph, or scan that can be used to diagnose amyloidosis; hence, awareness of the disease is necessary to identify patients with amyloidosis.[1]

Laboratory Findings

The following are the laboratory tests included in the management of cardiac amyloidosis:

  • Complete blood count: Normocytic normochromic anemia may be present
  • Serum troponins: Cardiac troponins are elevated due to myonecrosis and small-vessel disease due to deposition of amyloid in the heart. Troponins are of both diagnostic and prognostic importance. Studies have shown worse survival rates in patients with systemic amyloidosis and cardiac involvement compared to those without cardiac involvement.
  • Atrial natriuretic peptide: Elevated in heart failure
  • Brain natriuretic peptide: Elevated in heart failure. N-terminal proBNP is the most sensitive marker of heart dysfunction in amyloid patients.
  • Serum transthyretin
  • Urinalysis for proteinuria
  • Serum and urine electrophoresis
  • Serum and urine immunofixation
  • Serum electrolytes

References

  1. Hawkins PN (1997). "The diagnosis, natural history and treatment of amyloidosis. The Goulstonian Lecture 1995". Journal of the Royal College of Physicians of London. 31 (5): 552–60. PMID 9429195. |access-date= requires |url= (help)


Template:WikiDoc Sources